Accuracy of perceptions of hepatitis B and C statusBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7233.512 (Published 19 February 2000) Cite this as: BMJ 2000;320:512
Injecting drug users need vaccination against hepatitis B
- M E Ramsay, consultant epidemiologist (firstname.lastname@example.org),
- M A Balogun, clinical scientist,
- C G Teo, consultant virologist,
- P P Mortime, director
- Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ
- Hepatitis and Retrovirus Laboratory, PHLS Central Public Health Laboratory, London NW9 5HT
- Department of Social Science and Medicine, Imperial College School of Medicine, London W2 1PG
- Department of General Practice and Primary Care, University of Birmingham, Birmingham B15 2TT
- Department of Public Health, Rotherham Health Authority, Rotherham S60 3AQ
- Royal Hallamshire Hospital, Sheffield S10 2JF
- Institute of Psychiatry, National Addiction Centre, London SE5 8AF
EDITOR—Best et al give us useful information about drug users' perceptions of their hepatitis B and C status and, on the basis of this, recommend that clinicians should test all drug users for hepatitis B and C infection.1 With respect to hepatitis B, however, they fail to mention a more important intervention—namely, immunisation against hepatitis B.
This oversight may partly stem from their failure to distinguish current from past infection. We assume (although they do not state) that by “positive for hepatitis B virus” they mean that the serum was positive for antibody to hepatitis B core antigen. Alone, this marker signifies infection at some time in the past and probable protection against subsequent infection. The marker of active infection (and therefore infectiousness) is hepatitis B surface antigen. Among those infected by drug use one would expect less than a tenth of those with antibody to hepatitis B core antigen to also be positive for hepatitis B surface antigen.2
Drug users who are positive for antibody to hepatitis B core antigen but negative for hepatitis B surface antigen might correctly be informed that they are not at risk of the sequelae of chronic hepatitis B. They might also be told that they are no longer at risk of hepatitis B and that vaccination is unnecessary. Commercial assays for antibody to hepatitis B core antigen may, however, result in false positive test results,3 and patients at risk may therefore be denied the protection of a safe and effective vaccine. A positive result of a test for antibody to surface antigen is a more reliable marker of immunity.
Before recommending widespread testing of drug users we need to know whether knowledge of hepatitis status changes behaviour. In the study of Best et al a high proportion …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.